Abstract: Disclosed is nicotine containing solid oral transmucosal dosage forms containing a therapeutically effective amount of nicotine polacrilex, citric acid monohydrate, sucrose and liquid glucose. The dosage form is preferably in the form of lozenge.

Abstract: Disclosed is nicotine containing solid oral transmucosal dosage forms containing a therapeutically effective amount of nicotine polacrilex, citric acid monohydrate, sucrose and liquid glucose. The dosage form is preferably in the form of lozenge.

Abstract: The present invention describes a novel controlled release multilayer composition that is capable of delivering a first active agent from one layer immediately followed by continuous controlled delivery of second active agent from matrix forming layer while the dosage form floats and is retained in the fluid of the environment. The floating bilayer system comprises of immediate release layer containing one active agent and a disintegrating agent whereas second floating matrix forming layer comprises a gas generating component, a gelling agent, and a second active agent. The present invention relates more particularly to a controlled release fluoroquinolone compositions, which maintain a therapeutically effective blood concentration of fluoroquinolone for duration with once a day administration.

Abstract: The present invention relates to an herbal composition which is non-alcoholic, non-sedating and non-freezing in nature for the treatment of chronic respiratory disorders such as cold, cough, allergic asthma, seasonal allergic rhinitis, pharyngitis, laryngitis and the like and a process for preparing the same. The process comprises procuring, cleaning, grading of specified herbal plants per the standard specification, disintegrating and pulverizing separately to form coarse powder, then macerating individual powders separately with aqueous solution of preservatives, then extracting, filtering, concentrating and spray drying to make dry extract powder or semisolid soft extract. Further dissolving each of the extracts separately in aqueous solution containing preservatives and then allowing to maturate after mixing. Then adding filtered extracts to the sugar syrup containing preservatives, glycerin and appropriate excipients to obtain a homogenous cough syrup.

Abstract: Bilayer tablet comprising an immediate release first layer comprising an effective amount of oxcarbazepine and at least one pharmaceutically acceptable excipients and a controlled release second layer comprising an effective amount of oxcarbazepine and pharmaceutically acceptable excipients wherein the total amount of oxcarbazepine impurities is less than or equal to about 2% by weight. A process for preparation of controlled release bilayer tablets is capable of delivering oxcarbazepine from one layer immediately followed by a controlled delivery of oxcarbazepine from a matrix forming layer, and a process for preparation of oxcarbazepine bilayer tablets. Bilayer tablets of oxcarbazepine, which maintain a therapeutically effective blood concentration of oxcarbazepine with once a day administration.

Abstract: A novel pharmaceutical dental composition including diclofenac and chlorhexidine gluconate intended for pain associated with various diseases, comprising the diclofenac in its salt form and the chlorhexidine, and in addition a mucoadhesive agent in a pharmaceutically acceptable vehicle providing for bio-adhesion of the composition. One or more local anesthetics such a lidocaine and benzocaine, etc. may also optionally be included.

Abstract: The present invention describes a novel controlled release multilayer composition that is capable of delivering a first active agent from one layer immediately followed by continuous controlled delivery of second active agent from matrix forming layer while the dosage form floats and is retained in the fluid of the environment. The floating bilayer system comprises of immediate release layer containing one active agent and a disintegrating agent whereas second floating matrix forming layer comprises a gas generating component, a gelling agent, and a second active agent. The present invention relates more particularly to a controlled release fluoroquinolone compositions, which maintain a therapeutically effective blood concentration of fluoroquinolone for duration with once a day administration.

Abstract: A pharmaceutical composition for topical application and manufacturing process thereof for treatment of microbial and mycotic infections caused by aerobic and anaerobic microorganisms is provided comprising metronidazole and Povidone-Iodine, in effective amounts. Such a composition can be administered topically to patients in need thereof in various pharmaceutical dosage forms.

Abstract: The present invention relates to herbal composition for the treatment of chronic respiratory disorders such as cold, cough, allergic asthma, seasonal allergic rhinitis, pharyngitis, laryngitis and the like and a process for preparing the same.

Abstract: The present invention provides a novel floating osmotic device that is capable of delivering a first active agent in an outer coat immediately followed by continuous controlled delivery of second active agent from the osmotic core while the dosage form floats in the fluid of the environment. The floating osmotic device has of a compressed core containing active agent, a semipermeable membrane surrounding the core that is permeable to surrounding fluid and impermeable to the active agent, and an outer coating of a gas generating ingredient, a gelling agent, and a second active agent. Particular embodiments of the invention provide floating osmotic devices in which all two active agents are similar or dissimilar.

Abstract: A class of compounds particularly diaryl pyrazole of general formulas 1 and 2 where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N- alkylsulfamyl, N-arylsulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N-dialkylamido, N-alkyl-N-arylamido, N,N-dialkylsulfamyl with the alkyl, or alkyl part of each such group containing 1-3 carbon atoms or mixtures thereof optionally their salts when they exist, and preparation thereof. The compounds of the present invention are antiinflammatory, antipyretic, antirheumatic, antiosteoarthritic agents with antibacterial activity. The particular class of compounds is given below (Formula 1 and Formula 2).

Abstract: Pharmaceutical dental gel preparation comprising of metronidazole benzoate, chlorhexidine gluconate, and local anesthetic as the active ingredient; glycol as the solvent medium; a carboxyvinyl polymer, cross-linked polymer of acrylic acid copolymerized with polyalkylsucrose as a gelling agent.

Abstract: A class of compounds particularly diaryl pyrazole of general formulas 1 and 2 where R and R′ represents alkyl, hydrogen, halogens, haloalkyl, cyano, nitro, formyl, carboxyl, alkoxycarbonyl, carboxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, alkylthio, alkylsulfinyl, alkylsulphonyl, N- alkylsulfamyl, N-arylsulfamyl, cyanoamido, amino, amidino, N-monoalkylamido, N-monoarylamido, N,N-dialkylamido, N-alkyl-N-arylamido, N, N-dialkylsulfamyl with the alkyl, or alkyl part of each such group containing 1-3 carbon atoms or mixtures thereof optionally their salts when they exist, and preparation thereof.

Abstract: The present invention provides oral formulations of Ranitidine Hydrochloride in the form of coated tablets and capsules which produce controlled or regulated dissolution and release at a fairly uniform rate over long periods--as long as 12 to 24 hours--to maintain Ranitidine at desired levels above the MEC.